Floatz logo

Basiliximab

Graft-versus-host Disease (GVHD)

Zhongming Zhangmonoclonal_antibodyPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Graft-versus-host Disease (GVHD) cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
TACROLIMUS
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
Lactobacillus Plantarum Strain 299V
Children's Oncology Group
Phase 3B
Ruxolitinib
Xenikos
Phase 3B
Cyclophosphamide
Stanford University
Phase 2B

View all 14 →

Same molecule, other indications

Basiliximab is also rated in:

beta-thalassemia majorDormant
BB
Indicative ·
69 / 100
View asset →
Liver Transplant DisorderDormant
BB
Indicative ·
68 / 100
View asset →
Hodgkins lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →